LSU Health New Orleans Research Suggests New Approach for Treatment-Resistant Breast Cancers

August 09, 2023

triple-negative breast cancer cells

A study by researchers from LSU Health New Orleans School of Medicine, the University of Rochester, and biopharmaceutical company Cellestia Biotech AG suggests a promising new approach for dealing with certain treatment-resistant breast cancers.

Researchers said the study found compelling evidence that combining an investigational oral drug developed by Celestia with standard-of-care medications increased the treatment's effectiveness. Based on prior research, the LSU Health team believed the compound, CB-103, could be safe and effective in hormone-resistant estrogen-receptor-positive breast cancers and proposed the study to Cellestia.

LSU Health New Orleans has teaching, research, and health care functions state-wide, through its six professional schools and eight Centers of Excellence, as well as the more than one hundred affiliated hospitals and other health science related institutions throughout the state, region, nation, and the world.  

LEARN MORE About the Study